A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (Spinosad) for the Treatment of Scabies

Trial Profile

A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (Spinosad) for the Treatment of Scabies

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Spinosad (Primary)
  • Indications Scabies
  • Focus Registrational; Therapeutic Use
  • Sponsors ParaPRO
  • Most Recent Events

    • 30 May 2017 Planned End Date changed from 1 Jan 2018 to 1 Apr 2018.
    • 09 May 2017 Status changed from not yet recruiting to recruiting.
    • 10 Mar 2017 Planned number of patients changed from 75 to 120.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top